SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma jumps on reporting 43% rise in Q1 consolidated net profit

29 Jul 2022 Evaluate

Sun Pharma is currently trading at Rs. 941.10, up by 46.35 points or 5.18% from its previous closing of Rs. 894.75 on the BSE.

The scrip opened at Rs. 894.00 and has touched a high and low of Rs. 951.25 and Rs. 879.00 respectively. So far 442541 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 966.90 on 29-Apr-2022 and a 52 week low of Rs. 680.75 on 29-Jul-2021.

Last one week high and low of the scrip stood at Rs. 951.25 and Rs. 856.60 respectively. The current market cap of the company is Rs. 225753.43 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 34.61% and 10.91% respectively.

Sun Pharmaceutical Industries has reported net profit at Rs 1,011.80 crore for first quarter ended June 30, 2022 as compared to net loss of Rs 138.28 crore for the same quarter in the previous year. Total income of the company increased by 33.44% at Rs 4,981.87 crore for Q1FY23 as compared Rs 3,733.30 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 42.70% in its net profit after taxes, share of profit of associates and joint venture and non-controlling interests at Rs 2,060.88 crore for first quarter ended June 30, 2022 review as compared to Rs 1,444.17 crore for the same quarter in the previous year. Total income of the company increased by 9.04% at Rs 10,763.90 crore for Q1FY23 as compared Rs 9,871.26 crore for the corresponding quarter previous year.

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×